Cross-reactivity Hpv Types
Cross-reactivity Hpv Types - Related Videos
00:42
Cross-reactivity
0 Views •
2025
Overview The ability of a single antibody to recognize multiple structurally similar epitopes is an important immune defense strategy that enables the host to efficiently defend against many potentially threatening pathogens. However, cross-reactivity also elicits allergy symptoms against related allergens. It is increasingly important to understand the principles of cross-reactivity, as antibodies are actively being developed as therapeutic modalities for diverse diseases, including cancer.
10:44
Snap Chip for Cross-reactivity-free and Spotter-free Multiplexed Sandwich Immunoassays
0 Views •
Cited by 3 •
2017
We demonstrate a snap chip technology for performing cross-reactivity-free multiplexed sandwich immunoassays by simply snapping two slides. A snap apparatus is used for reliably transferring reagents from microarray-to-microarray. The snap chip can be used for any biochemical reactions requiring colocalization of different reagents without cross-contamination.
04:36
A Snap Chip Technology for a Cross-Reactivity-Free Multiplexed Sandwich Immunoassay
0 Views •
2025
The video showcases the implementation of snap chip technology for cross-reactivity-free multiplexed sandwich immunoassays. The simple action of snapping two microarray slides, each containing different reagents, ensures reagent transfer without cross-contamination and helps to detect multiple proteins using sandwich immunoassay.
12:30
Production of Nurr-1 Specific Polyclonal Antibodies Free of Cross-reactivity Against Its Close Homologs, Nor1 and Nur77
0 Views •
Cited by 4 •
2015
Here, we selectively target antibodies against a specific member of a highly conserved family of proteins by immunizing animals with their most divergent regions followed by removing cross reactive antibodies by pre-adsorption.
08:55
Making a Geologic Cross Section
0 Views •
2023
Source: Laboratory of Alan Lester - University of Colorado Boulder Geologic maps were first made and utilized in Europe, in the mid-to-late 18th century. Ever since, they have been an important part of geological investigations all around the world that strive to understand rock distributions on the surface of the earth, in the subsurface, and their modification through time. A modern geologic map is a data-rich representation of rocks and rock-structures in a two-dimensional plan view. The...
FAQs
Shared epitopes are the central molecular basis of cross-reactivity among HPV types. When related types present viral capsid regions with similar antigenic structure, antibodies raised against one type may bind the other, while T cells may recognize related antigenic features. This similarity explains why immune recognition can extend beyond the originally encountered type without guaranteeing complete protection.
Cross-reactive antibodies and T cells provide different types of evidence. An antibody finding indicates that immune molecules generated against one HPV type can bind antigens from another, whereas a T-cell finding indicates recognition and response to related antigens. Keeping these readouts distinct helps researchers avoid treating every cross-reactive signal as identical immune activity.
Recognition does not automatically mean equivalent protection. Shared or structurally similar epitopes can permit binding or cellular recognition, yet the response may interact less effectively with the non-original type. Consequently, cross-reactivity among HPV types must be evaluated in terms of both immune recognition and protective breadth, rather than assuming that one implies the other.
Cross-reactivity can complicate interpretation of serological and diagnostic assays. An assay may detect recognition of antigens from a related HPV type rather than uniquely indicating a response to the type under investigation. Researchers therefore consider related-type recognition when interpreting assay signals, helping distinguish broad immune reactivity from evidence specifically attributable to one HPV type.
Researchers compare immune recognition of vaccine-targeted HPV types with responses to related non-targeted types. This comparison helps assess whether vaccine-associated immunity extends beyond intended targets and whether that extension is sufficient to influence infection with other types. The key outcome is breadth of protection, not merely the presence of antigen recognition.
In infection studies, researchers can ask whether immunity generated against one HPV type is associated with recognition of, or possible influence on, infection involving another type. This approach places individual immune responses within a broader type-to-type context. It is especially relevant when evaluating non-targeted HPV types alongside vaccine-targeted or previously encountered types.